Amgen (AMGN) Stock
Large biotech company with established medicines and steady dividends. Here's the price, business snapshot, and what's worth knowing about Amgen in October 2026.
Amgen Inc (AMGN) is a large-cap biotechnology company specialising in human therapeutics, particularly biologic medicines. With a market capitalisation around $162 billion, Amgen generates revenue from established products across oncology, nephrology, inflammation and cardiovascular care, while investing heavily in a diverse R&D pipeline of biologics and novel therapies. The company benefits from recurring revenue from long-tenured biologics, a history of steady free cash flow and a shareholder-friendly dividend policy, but faces typical sector risks: clinical trial setbacks, biosimilar competition, pricing pressure and regulatory scrutiny. Investors should watch product patent expiries, pipeline readouts and any M&A activity. This summary is for educational purposes only and not personalised investment advice; suitability depends on an investor’s goals, timeframe and risk tolerance, and returns are not guaranteed.
Why It’s Moving
Amgen's Dividend Hike Masks Underlying Debt and Pipeline Pressures
- The company announced a 6% dividend increase, but this payout competes with a substantial mountain of acquisition debt and capital needs for legacy drug maintenance.
- A billion-dollar investment in an obesity treatment candidate is consuming resources, raising concerns about near-term liquidity despite strong medium-term prospects.
- Recent clinical trial results for promising candidates provided a boost to sentiment, helping shares rise 2.11% to close at $414.61, though technical support levels remain critical.
Amgen's Dividend Hike Masks Underlying Debt and Pipeline Pressures
- The company announced a 6% dividend increase, but this payout competes with a substantial mountain of acquisition debt and capital needs for legacy drug maintenance.
- A billion-dollar investment in an obesity treatment candidate is consuming resources, raising concerns about near-term liquidity despite strong medium-term prospects.
- Recent clinical trial results for promising candidates provided a boost to sentiment, helping shares rise 2.11% to close at $414.61, though technical support levels remain critical.
Sixth Month Growth Performance
When is the next earnings date for AMGEN INC (AMGN)?
Amgen has not yet confirmed a specific date for its next earnings release. Based on the company's historical reporting pattern of approximately three months between quarters, the upcoming report is expected in late October 2026. This announcement will cover financial results for the third quarter of fiscal year 2026. Investors should monitor official corporate communications for the precise scheduling of this event.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Amgen's stock, with a target price indicating a possible decline.
Financial Health
Amgen is performing very well with strong profits, cash flow, and revenue generation.
Dividend
Amgen's dividend yield of 2.43% offers a reasonable return for investors seeking dividends. If you invested $1000 you would be paid $24.30 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Established Biologics Revenue
Amgen’s marketed biologics provide recurring sales and predictable cash flow, though revenue can be affected by patent loss and biosimilar entrants.
Pipeline & R&D Focus
A deep R&D pipeline drives long-term potential; positive trial results can re-rate the business, while failures can materially affect value.
Global Market Exposure
Amgen sells worldwide, benefiting from geographic diversification, but faces regional pricing and regulatory differences that can influence performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
